Cargando…

Association of Occupational Pesticide Exposure With Immunochemotherapy Response and Survival Among Patients With Diffuse Large B-Cell Lymphoma

IMPORTANCE: Professional use of pesticides is a risk factor for non-Hodgkin lymphoma. The main biological mechanisms of pesticides and chemotherapy are genotoxicity and reactive oxygen species generation. Cellular adaptation among patients exposed to low doses of genotoxic and oxidative compounds mi...

Descripción completa

Detalles Bibliográficos
Autores principales:	Lamure, Sylvain, Carles, Camille, Aquereburu, Quam, Quittet, Philippe, Tchernonog, Emmanuelle, Paul, Franciane, Jourdan, Eric, Waultier, Agathe, Defez, Christine, Belhadj, Ihssen, Sanhes, Laurence, Burcheri, Sara, Donadio, Daniel, Exbrayat, Carole, Saad, Alain, Labourey, Jean-Luc, Baldi, Isabelle, Cartron, Guillaume, Fabbro-Peray, Pascale
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	American Medical Association 2019
Materias:	Original Investigation
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6481431/ https://www.ncbi.nlm.nih.gov/pubmed/31002318 http://dx.doi.org/10.1001/jamanetworkopen.2019.2093

Ejemplares similares

Current trends of anticancer immunochemotherapy
por: Vacchelli, Erika, et al.
Publicado: (2013)

Role of obinutuzumab exposure on clinical outcome of follicular lymphoma treated with first‐line immunochemotherapy
por: Jamois, Candice, et al.
Publicado: (2019)

Trial Watch: Lenalidomide-based immunochemotherapy
por: Semeraro, Michaela, et al.
Publicado: (2013)

Immunochemotherapy for Richter syndrome: current insights
por: Puła, Bartosz, et al.
Publicado: (2019)

Immunotherapy and immunochemotherapy in combating visceral leishmaniasis
por: Yadagiri, Ganesh, et al.
Publicado: (2023)

Bifidobacterium in anticancer immunochemotherapy: friend or foe?
por: Procaccianti, Giorgia, et al.
Publicado: (2023)

Clinical and Product Features Associated with Outcome of DLBCL Patients to CD19-Targeted CAR T-Cell Therapy
por: Lamure, Sylvain, et al.
Publicado: (2021)

Obinutuzumab Versus Rituximab Immunochemotherapy in Previously Untreated iNHL: Final Results From the GALLIUM Study
por: Townsend, William, et al.
Publicado: (2023)

An immunostimulatory dual-functional nanocarrier that improves cancer immunochemotherapy
por: Chen, Yichao, et al.
Publicado: (2016)

Immunotherapy and Immunochemotherapy in Visceral Leishmaniasis: Promising Treatments for this Neglected Disease
por: Roatt, Bruno Mendes, et al.
Publicado: (2014)

Drug screening approach combines epigenetic sensitization with immunochemotherapy in cancer
por: Facciotto, Chiara, et al.
Publicado: (2019)

Campylobacter fetus spondylodiscitis during immunochemotherapy for non-Hodgkin's lymphoma
por: Cunha, Jéssica Santos, et al.
Publicado: (2021)

The Feasibility of Virtual Toxicity Assessments in Lymphoma Patients Receiving Immunochemotherapy
por: Runge, John S., et al.
Publicado: (2020)

Ibrutinib Associated with Rituximab-Platinum Salt-Based Immunochemotherapy in B-Cell Lymphomas: Results of a Phase 1b-II Study of the LYSA Group
por: Bonnet, Christophe, et al.
Publicado: (2022)

Novel combination immunochemotherapy beyond CD20 for B-cell lymphomas
por: Yi, Jun Ho
Publicado: (2021)

Diverse effects of chemotherapeutic agents on immune cell function and implications in immunochemotherapy
por: Glorieux, Christophe, et al.
Publicado: (2021)

Evolving frontline immunochemotherapy for mantle cell lymphoma and the impact on survival outcomes
por: Castellino, Alessia, et al.
Publicado: (2022)

Severe Post-COVID-19 Organizing Pneumonia during Cancer Immunochemotherapy
por: Kitahara, Asako, et al.
Publicado: (2022)

Hypofractionated radiotherapy with immunochemotherapy for extensive-stage small-cell lung cancer
por: Liu, Chaoyuan, et al.
Publicado: (2023)

Indoleamine 2, 3-dioxygenase inhibitors in immunochemotherapy of breast cancer: challenges and opportunities
por: Hashemzadeh, Nastran, et al.
Publicado: (2019)

Esophageal Stricture Following Radiation, Concurrent Immunochemotherapy, Treated With Hyperbaric Oxygen and Dilation
por: Ajayi, Olayinka D., et al.
Publicado: (2019)

Inorganic Nanozyme with Combined Self-Oxygenation/Degradable Capabilities for Sensitized Cancer Immunochemotherapy
por: Wang, Jie, et al.
Publicado: (2019)

Relapsing Cutaneous Multiple Myeloma Responding to Immunochemotherapy: A Rare Case Report
por: Mohamed, Mujtaba, et al.
Publicado: (2019)

Adrenal insufficiency in immunochemotherapy for small-cell lung cancer with ectopic ACTH syndrome
por: Nakajima, Hiroki, et al.
Publicado: (2021)

Dramatic response to immunochemotherapy followed by salvage surgery in an elderly lung cancer patient
por: Okano, Yoshio, et al.
Publicado: (2021)

An integrated prognostic model for diffuse large B‐cell lymphoma treated with immunochemotherapy
por: Rodríguez, Marta, et al.
Publicado: (2022)

A novel immunochemotherapy based on immunogenicity-activated and immunosuppression-reversed biomimetic nanoparticles
por: Zuo, Huaqin, et al.
Publicado: (2022)

A case report of small cell ovarian neuroendocrine carcinoma combined with immunochemotherapy
por: Zhu, Yuan-Xue, et al.
Publicado: (2022)

Evaluation of 4 prognostic indices in follicular lymphoma treated in first line with immunochemotherapy
por: Rodríguez-Sevilla, Juan Jose, et al.
Publicado: (2022)

Expanding the role of combined immunochemotherapy and immunoradiotherapy in the management of head and neck cancer (Review)
por: Wei, Chun, et al.
Publicado: (2023)

Pourquoi tuer le pépé?
por: Exbrayat
Publicado: (1972)

Outcomes after (90)Yttrium-ibritumomab tiuxetan-BEAM in diffuse large B-cell lymphoma: a meta-analysis
por: Auger-Quittet, Sophie, et al.
Publicado: (2014)

Human herpesvirus-6 pneumonitis in a patient with follicular lymphoma following immunochemotherapy with rituximab
por: Kuwahara-Ota, Saeko, et al.
Publicado: (2018)

Vitamin D deficiency and supplementation in patients with aggressive B‐cell lymphomas treated with immunochemotherapy
por: Hohaus, Stefan, et al.
Publicado: (2017)

Novel galenic formulations for delivering immunochemotherapies: kill intelligently, remove the checkpoint and let the T cells in!
por: Kepp, Oliver, et al.
Publicado: (2020)

Impact of complete surgical resection on outcome in aggressive non‐Hodgkin lymphoma treated with immunochemotherapy
por: Schmitz, Christine, et al.
Publicado: (2020)

Protective Cellular Immune Response Induction for Cutaneous Leishmaniasis by a New Immunochemotherapy Schedule
por: da Silva, Danielle A. M., et al.
Publicado: (2020)

IL-2 complex recovers steroid-induced inhibition in immunochemotherapy for head and neck cancer
por: Kono, Michihisa, et al.
Publicado: (2022)

COVID-19 in Patients Receiving CD20-depleting Immunochemotherapy for B-cell Lymphoma
por: Gaitzsch, Erik, et al.
Publicado: (2021)

Risk of diabetes and the impact on preexisting diabetes in patients with lymphoma treated with steroid-containing immunochemotherapy
por: Baech, Joachim, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_0sb6i59jn7cuqao5ibrlnl2a5m